From the Food and Drug Administration.
Nightingale
S L
SL
D000485:Allergens; D000998:Antiviral Agents / Q000627:therapeutic use*; D020117:Cisapride; D000075202:Contraindications; D003888:Desensitization, Immunologic; D004348:Drug Labeling; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008327:Mammography / Q000295:instrumentation*; D010880:Piperidines / Q000009:adverse effects*; D006109:Poaceae; D011058:Pollen; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000485:Allergens; D000998:Antiviral Agents; D005765:Gastrointestinal Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010880:Piperidines; D011994:Recombinant Proteins; D012254:Ribavirin; D020117:Cisapride